As countries worldwide relax the measures they had put in place to contain the COVID-19 epidemic, on June 21, WHO recorded the largest yet 24-h increase in global cases. Just over a week earlier, China had reported a new outbreak in Beijing, after almost 2 months without local transmissions. These events are stark reminders to countries that believe they have overcome the worse, that the pandemic is not over and now is not a time to be complacent. The possibility of returning to a truly pre-pandemic lifestyle relies on the development and widespread availability of a vaccine or treatment.

17 candidate vaccines are currently undergoing [trials](https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/){#interrefs40}. Some countries, such as the USA and the UK, have invested substantial government funds to secure large numbers of doses of vaccines that are currently in phase 2 or 3 trials, as Tony Kirby reports in a News piece in this issue. Public financial support has been crucial in facilitating extraordinarily rapid development and trialling of candidate vaccines. However, all hope should not be placed on a vaccine as there is no guarantee that one will be effective. Similarly, the announcement on June 16 of the efficacy of the corticosteroid dexamethasone in reducing mortality among critically ill patients with COVID-19 has been welcomed, but the true game-changer would be identification of a therapy that is effective in most patients, and particularly one that prevents mild disease from becoming severe.

As research efforts to develop vaccines and therapies continue, in countries where the first wave of the pandemic is subsiding, governments are trying to balance the easing of restrictions to rekindle the economy with preserving (and improving) the results achieved through said restrictions. Since relatively early in the pandemic, the UK Government has stated that antibody testing should be central to relaxing the lockdown, and it has recently negotiated the acquisition of over 10 million Elecsys Anti-SARS-CoV-2 tests (Roche, Basel, Switzerland) to deploy in the UK. Antibody tests reveal the presence of SARS-CoV-2-specific antibodies, suggesting prior infection. Positive test results have been touted as indicative of immunity against future infection, which would provide individuals with a so-called immunity passport that would allow them to return to a normal lifestyle. However, even without considering the logistical and ethical implications of issuing immunity passports, to date there is limited evidence of a protective effect conferred by SARS-CoV-2 antibodies.

Nevertheless, antibody testing can be useful. If done at a population level, it can provide valuable information about the prevalence of SARS-CoV-2 infection, regardless of symptoms. This information can be used to assess whether herd immunity levels have been reached and to calculate more accurate estimates of the basic reproduction number and infection fatality ratio, thus improving the understanding of the epidemiology of COVID-19. By testing samples from adult blood donors across England, [Public Health](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/888254/COVID19_Epidemiological_Summary_w22_Final.pdf){#interrefs10} England estimated the seroprevalence to be less than 10% in most parts of the country, and 15% in London, in May. Assuming the tested cohort is representative of the overall English population, these estimates are well below those needed for herd immunity (about 60--80%). [Other countries in Europe](https://doi.org/10.1016/S0140-6736(20)31357-X){#interrefs20} have similarly found seroprevalence estimates of about 10% or less.

Low seroprevalence values in different countries indicate that most of the population is still susceptible to infection. As these countries relax restrictions, it is imperative that they ensure other measures are in place to contain the resurgence of cases and avoid having to impose a new lockdown on already weakened societies. The South Korean success in containing the number of cases and deaths without enforcing a full national lockdown, and the results of mathematical [modelling](https://doi.org/10.1016/S1473-3099(20)30457-6){#interrefs30}, unsurprisingly support the rigorous adoption of the test, trace, and isolate strategy, combined with physical distancing and hygiene measures, as the best approach to prevent a second wave of infections.

In essence, at a time when efficacy has not yet been shown for any candidate vaccine, no universal treatment has been identified, population-level immunity has not been reached, and countries cannot afford another full lockdown, the established public health approach of hand-washing, maintaining physical distancing, and testing and isolating infectious cases and their contacts from the broader community remains the key to managing and containing the spread of COVID-19. We might be reiterating the obvious, but the stakes are too high to take the basics for granted.
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